Egetis Therapeutics secured US FDA approval for its emcitate/ tiratricol therapy for a rare X-linked genetic condition. The approval is a milestone for the company’s effort to bring a treatment option to patients with short life expectancy, underscoring the continued role of orphan pathways in advancing gene and metabolic disorder therapeutics.